Ouabain stimulates endothelin release and expression in human endothelial cells without inhibiting the sodium pump

Ouabain, a sodium pump (Na + / K + ‐ATPase) inhibitor, has been shown to act as a hormone and is possibly involved in the pathogenesis of hypertension. The mechanism by which ouabain may act was investigated using primary cultures of human umbilical artery endothelial cells (HUAECs), which are known to express and release the vasoconstrictive hormone endothelin (ET‐1). Five minutes after application, low concentrations of ouabain induced Ca 2+ oscillations and stimulated ET‐1 release from endothelial cells into the medium. To investigate whether the observed effects were due to inhibition of the sodium pump, the effects of ouabain on the uptake of 86 Rb + by HUAECs were examined. Unexpectedly, ouabain concentrations below 10 n m stimulated 86 Rb + uptake by 15–20%, and in some experiments by 50%, results that are consistent with a stimulation of the pump. Within the concentration range 1–10 n m , ouabain induced a 2.5‐fold stimulation (phosphorylation) of mitogen‐activated protein kinase (MAP kinase). After incubation of HUAECs with ouabain for 12 h, the glycoside stimulated cell growth by 49 ± 4%, as measured by cell number, with a maximum response at 5 n m . At similar concentrations, ouabain also increased ET‐1 mRNA abundance by 19.5 ± 3.1%. The results indicate that, by influencing ET‐1 expression and release, ouabain may contribute to the regulation of vascular tone. The data also confirm that it is not a global inhibition of the sodium pump that is involved in the mechanism of action of this cardiac glycoside.